Fibromyalgia: one year in review 2025
Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive research, its pathogenesis and treatment remain only partially understood, driving continued investigation throughout 2024. Dysregulation of the h...
Uložené v:
| Vydané v: | Clinical and experimental rheumatology Ročník 43; číslo 6; s. 957 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Italy
01.06.2025
|
| Predmet: | |
| ISSN: | 0392-856X |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive research, its pathogenesis and treatment remain only partially understood, driving continued investigation throughout 2024. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system has been linked to chronic stress responses and neuroinflammation, with neuroimaging and preclinical studies confirming altered pain and stress processing. Low-grade inflammation and metabolic disturbances, including cytokine imbalance and increased adipose tissue infiltration, further exacerbate symptoms. Alterations in the gut microbiota contribute to immune and emotional dysregulation. MRI studies continue to reveal brain changes that differentiate FM from other chronic pain disorders. Multi-omics approaches, including transcriptomic and metabolomic analyses, show promise as diagnostic biomarkers. Mitochondrial dysfunction also emerges as a key factor, since impaired energy metabolism seems to correlate with symptom severity. From a clinical perspective, recent studies have explored under-recognised aspects of FM, such as sexual and cognitive dysfunction, the role of gender, environmental exposures, and the disease's impact on relationships and family life. The differential diagnosis of FM and long COVID has ignited discussion about potential shared mechanisms. Conversely, residual pain in inflammatory diseases remains insufficiently addressed. Therapeutically, non-pharmacological strategies, particularly physical activity and psychosocial interventions, remain fundamental. Emerging areas such as non-invasive neuromodulation, psychedelic therapies, and the integration of technologies like virtual reality and artificial intelligence are opening new frontiers in treatment, patient care, and research. These advances underscore the multifactorial nature of FM and the need for personalised, interdisciplinary approaches. |
|---|---|
| AbstractList | Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive research, its pathogenesis and treatment remain only partially understood, driving continued investigation throughout 2024. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system has been linked to chronic stress responses and neuroinflammation, with neuroimaging and preclinical studies confirming altered pain and stress processing. Low-grade inflammation and metabolic disturbances, including cytokine imbalance and increased adipose tissue infiltration, further exacerbate symptoms. Alterations in the gut microbiota contribute to immune and emotional dysregulation. MRI studies continue to reveal brain changes that differentiate FM from other chronic pain disorders. Multi-omics approaches, including transcriptomic and metabolomic analyses, show promise as diagnostic biomarkers. Mitochondrial dysfunction also emerges as a key factor, since impaired energy metabolism seems to correlate with symptom severity. From a clinical perspective, recent studies have explored under-recognised aspects of FM, such as sexual and cognitive dysfunction, the role of gender, environmental exposures, and the disease's impact on relationships and family life. The differential diagnosis of FM and long COVID has ignited discussion about potential shared mechanisms. Conversely, residual pain in inflammatory diseases remains insufficiently addressed. Therapeutically, non-pharmacological strategies, particularly physical activity and psychosocial interventions, remain fundamental. Emerging areas such as non-invasive neuromodulation, psychedelic therapies, and the integration of technologies like virtual reality and artificial intelligence are opening new frontiers in treatment, patient care, and research. These advances underscore the multifactorial nature of FM and the need for personalised, interdisciplinary approaches. Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive research, its pathogenesis and treatment remain only partially understood, driving continued investigation throughout 2024. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system has been linked to chronic stress responses and neuroinflammation, with neuroimaging and preclinical studies confirming altered pain and stress processing. Low-grade inflammation and metabolic disturbances, including cytokine imbalance and increased adipose tissue infiltration, further exacerbate symptoms. Alterations in the gut microbiota contribute to immune and emotional dysregulation. MRI studies continue to reveal brain changes that differentiate FM from other chronic pain disorders. Multi-omics approaches, including transcriptomic and metabolomic analyses, show promise as diagnostic biomarkers. Mitochondrial dysfunction also emerges as a key factor, since impaired energy metabolism seems to correlate with symptom severity. From a clinical perspective, recent studies have explored under-recognised aspects of FM, such as sexual and cognitive dysfunction, the role of gender, environmental exposures, and the disease's impact on relationships and family life. The differential diagnosis of FM and long COVID has ignited discussion about potential shared mechanisms. Conversely, residual pain in inflammatory diseases remains insufficiently addressed. Therapeutically, non-pharmacological strategies, particularly physical activity and psychosocial interventions, remain fundamental. Emerging areas such as non-invasive neuromodulation, psychedelic therapies, and the integration of technologies like virtual reality and artificial intelligence are opening new frontiers in treatment, patient care, and research. These advances underscore the multifactorial nature of FM and the need for personalised, interdisciplinary approaches.Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive research, its pathogenesis and treatment remain only partially understood, driving continued investigation throughout 2024. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system has been linked to chronic stress responses and neuroinflammation, with neuroimaging and preclinical studies confirming altered pain and stress processing. Low-grade inflammation and metabolic disturbances, including cytokine imbalance and increased adipose tissue infiltration, further exacerbate symptoms. Alterations in the gut microbiota contribute to immune and emotional dysregulation. MRI studies continue to reveal brain changes that differentiate FM from other chronic pain disorders. Multi-omics approaches, including transcriptomic and metabolomic analyses, show promise as diagnostic biomarkers. Mitochondrial dysfunction also emerges as a key factor, since impaired energy metabolism seems to correlate with symptom severity. From a clinical perspective, recent studies have explored under-recognised aspects of FM, such as sexual and cognitive dysfunction, the role of gender, environmental exposures, and the disease's impact on relationships and family life. The differential diagnosis of FM and long COVID has ignited discussion about potential shared mechanisms. Conversely, residual pain in inflammatory diseases remains insufficiently addressed. Therapeutically, non-pharmacological strategies, particularly physical activity and psychosocial interventions, remain fundamental. Emerging areas such as non-invasive neuromodulation, psychedelic therapies, and the integration of technologies like virtual reality and artificial intelligence are opening new frontiers in treatment, patient care, and research. These advances underscore the multifactorial nature of FM and the need for personalised, interdisciplinary approaches. |
| Author | Lucini, Daniela Di Franco, Manuela Iannuccelli, Cristina Favretti, Martina Dolcini, Giulio Di Carlo, Marco Atzeni, Fabiola Varassi, Giustino Conti, Fabrizio Sarzi-Puttini, Piercarlo Leoni, Matteo Luigi Giuseppe Bazzichi, Laura Salaffi, Fausto Pellegrino, Greta Fornasari, Diego Maria Michele |
| Author_xml | – sequence: 1 givenname: Cristina surname: Iannuccelli fullname: Iannuccelli, Cristina organization: Rheumatology Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Italy – sequence: 2 givenname: Martina surname: Favretti fullname: Favretti, Martina email: martina.favretti@uniroma1.it organization: Department of Molecular Medicine, Sapienza University of Rome, Italy. martina.favretti@uniroma1.it – sequence: 3 givenname: Giulio surname: Dolcini fullname: Dolcini, Giulio organization: Department of Molecular Medicine, Sapienza University of Rome, Italy – sequence: 4 givenname: Marco surname: Di Carlo fullname: Di Carlo, Marco organization: Rheumatology Unit, Università Politecnica delle Marche, Carlo Urbani Hospital, Jesi (Ancona), Italy – sequence: 5 givenname: Greta surname: Pellegrino fullname: Pellegrino, Greta organization: Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan; and Department of Biomedical and Clinical Sciences, University of Milan, Italy – sequence: 6 givenname: Laura surname: Bazzichi fullname: Bazzichi, Laura organization: Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy – sequence: 7 givenname: Fabiola surname: Atzeni fullname: Atzeni, Fabiola organization: Rheumatology Unit, Department of Internal and Experimental Medicine, University of Messina, Italy – sequence: 8 givenname: Daniela surname: Lucini fullname: Lucini, Daniela organization: BIOMETRA Department, University of Milan; and IRCCS Istituto Auxologico Italiano, Exercise Medicine Unit, Milan, Italy – sequence: 9 givenname: Giustino surname: Varassi fullname: Varassi, Giustino organization: Paolo Procacci Foundation, Rome, Italy – sequence: 10 givenname: Matteo Luigi Giuseppe surname: Leoni fullname: Leoni, Matteo Luigi Giuseppe organization: Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy – sequence: 11 givenname: Diego Maria Michele surname: Fornasari fullname: Fornasari, Diego Maria Michele organization: Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy – sequence: 12 givenname: Fabrizio surname: Conti fullname: Conti, Fabrizio organization: Rheumatology Unit, Department of Clinical Internal, Anaesthesiologic and Cardiovascolar Sciences, Sapienza University of Rome, Italy – sequence: 13 givenname: Fausto surname: Salaffi fullname: Salaffi, Fausto organization: Rheumatology Unit, Università Politecnica delle Marche, Carlo Urbani Hospital, Jesi (Ancona), Italy – sequence: 14 givenname: Piercarlo surname: Sarzi-Puttini fullname: Sarzi-Puttini, Piercarlo organization: Department of Rheumatology, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan; and Department of Biomedical and Clinical Sciences, University of Milan, Italy – sequence: 15 givenname: Manuela surname: Di Franco fullname: Di Franco, Manuela organization: Rheumatology Unit, Department of Clinical Internal, Anaesthesiologic and Cardiovascolar Sciences, Sapienza University of Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40470564$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j7tOwzAUQD0U0Qf8AsqCxBLqOL52zIYqCkiVWDqwRX7cUKO8sBMgfD2VKNNZjo50lmTWdi0SkmT0FgBEvra1b_G7DwccGz109dqMB8d-ZmRBc8XSAsTrnCxjfKeUCRDynMw55ZKC4AtyvfUmdM2k6zev75JjOplQh8S3ScBPj18JowwuyFml64iXJ67Ifvuw3zylu5fH5839LrW5kENqbOGqSmTMCc0cOCs1AKJS3EDGGOYVgjGVNrniWECmjSgklxylpdYhW5Gbv2wfuo8R41A2Plqsa91iN8YyZxkoRaXKjurVSR1Ng67sg290mMr_M_YLrqNUnA |
| CitedBy_id | crossref_primary_10_56941_odutip_1725934 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.55563/clinexprheumatol/buhd2z |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 40470564 |
| Genre | Journal Article Review |
| GroupedDBID | --- 29B 53G 5GY 5RE 8RF AAFWJ AATUM ADBBV AENEX AEODN AFFNX ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CUY CVF DIK ECM EIF EJD F5P FRP NPM P2P P6G RVY SJN TR2 W2D XRB ZGI ZXP ~4P 7X8 |
| ID | FETCH-LOGICAL-c367t-bc8dff612d6a2d5dc7a55ee994b5122e3fe5bbfab394e851ab687474e7c0cde2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 7 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001523342100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0392-856X |
| IngestDate | Thu Jun 05 17:32:02 EDT 2025 Sun Jun 29 01:31:21 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c367t-bc8dff612d6a2d5dc7a55ee994b5122e3fe5bbfab394e851ab687474e7c0cde2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.clinexprheumatol.org/article.asp?a=22545 |
| PMID | 40470564 |
| PQID | 3215990791 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3215990791 pubmed_primary_40470564 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-01 |
| PublicationDateYYYYMMDD | 2025-06-01 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Italy |
| PublicationPlace_xml | – name: Italy |
| PublicationTitle | Clinical and experimental rheumatology |
| PublicationTitleAlternate | Clin Exp Rheumatol |
| PublicationYear | 2025 |
| SSID | ssj0026567 ssj0000684810 |
| Score | 2.4705555 |
| SecondaryResourceType | review_article |
| Snippet | Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, high prevalence, and a significant impact on quality of life. Despite extensive... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 957 |
| SubjectTerms | COVID-19 - epidemiology Fibromyalgia - diagnosis Fibromyalgia - epidemiology Fibromyalgia - physiopathology Fibromyalgia - psychology Fibromyalgia - therapy Humans Quality of Life |
| Title | Fibromyalgia: one year in review 2025 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40470564 https://www.proquest.com/docview/3215990791 |
| Volume | 43 |
| WOSCitedRecordID | wos001523342100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGA_qRLz4fswXFfQY1qZJk3gREYcHN3YY0ltJmlQHs517iPOv90vbzZMgeCm5JGle3_f73ghdSSU411RgTYwLyTEGK2jiUMJ5Z5QRWmZien7i3a6IY9mrFW6T2q1yQRNLQm2K1OnIWyHwJqCcXAa3o3fsqkY562pdQmMVNUKAMs6li8diqWPxI5cs3l8KYIBdyvBpwARYsCiuPHuYy5HVcoGI9nM0frUzgIrFsKVnr4Z8_Q48SwbU3v7vr--grRp6enfVXdlFKzbfQxud2ri-j67bIDoXb3M1fBmoG6_IrTeHd-ANcq8KcPEIQJcD1G8_9O8fcV1FAadhxKdYp8JkGQAZEylimEm5YsxaKakGZk9smFmmdaZ0KKkF_KV0JEDGoJanfmosOURrOcx4jDzBpbVE-hJGoEoR14sHUhrL_CAjQRNdLtafwCV1lgeV22I2SX52oImOqk1MRlU2jYT6lAMKoyd_6H2KNt1KK1etM9TI4Inac7SefkwHk_FFefrw7fY63yfMuKg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fibromyalgia%3A+one+year+in+review+2025&rft.jtitle=Clinical+and+experimental+rheumatology&rft.au=Iannuccelli%2C+Cristina&rft.au=Favretti%2C+Martina&rft.au=Dolcini%2C+Giulio&rft.au=Di+Carlo%2C+Marco&rft.date=2025-06-01&rft.issn=0392-856X&rft_id=info:doi/10.55563%2Fclinexprheumatol%2Fbuhd2z&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0392-856X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0392-856X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0392-856X&client=summon |